Lembke, known for her work on addiction, discusses what FDA-approved GLP-1 weight loss drugs could do beyond weight. Details are on Stanford Medicine.
Recap by typeshit. Post by Stanford Medicine on X.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
A Penn study in JAMA Health Forum compared 9 covering states with 36 that don't. Obesity-labeled scripts rose, but total GLP-1 use grew by less.
Users most often reported increased appetite, unlike the stomach issues seen in trials. The researchers say it can't show retatrutide caused any of it.
Loading…